Amgen EPO Medicare Claims To Be Monitored Via Dose Levels – CMS Draft
Executive Summary
Medicare claims for use of Amgen's Aranesp and Epogen in end-stage renal disease will be monitored through blood hematocrit or hemoglobin levels as well as dosage levels, a Centers for Medicare & Medicaid Services' draft policy says
You may also be interested in...
EPO Part B Claims Reimbursement To Follow Labeling On Dose Reduction
The Centers for Medicare & Medicaid Services' final policy on Part B reimbursement for Amgen's Aranesp (darbepoetin alfa) and Epogen (epoeitin alfa) in end-stage renal disease follows product labeling recommendations that dosing be reduced when hematocrit levels reach a certain threshold
EPO Part B Claims Reimbursement To Follow Labeling On Dose Reduction
The Centers for Medicare & Medicaid Services' final policy on Part B reimbursement for Amgen's Aranesp (darbepoetin alfa) and Epogen (epoeitin alfa) in end-stage renal disease follows product labeling recommendations that dosing be reduced when hematocrit levels reach a certain threshold
Medicare Payments For Unbundled Drugs Needs Revision, MedPAC Says
The Centers for Medicare & Medicaid Services should change how it sets payments for unbundled hospital outpatient drugs once a provision in the 2003 Medicare law expires, the Medicare Payment Advisory Commission said